Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

1126 - Is right-sided (sRt) BRAF mutated (mBRAF) metastatic colorectal cancer (mCRC) unresponsive to the 1st-line antiEGFR antibody treatment?

Date

24 Nov 2018

Session

Poster display - Cocktail

Presenters

Ryo Kudo

Citation

Annals of Oncology (2018) 29 (suppl_9): ix28-ix45. 10.1093/annonc/mdy431

Authors

R. Kudo

Author affiliations

  • Surgery, Kyoto-Katsura Hospital, 615-8256 - Kyoto/JP
More

Resources

Abstract 1126

Background

Recently, sidedness and BRAF status of mCRC has been discussed most because they have strong correlations with the treatment effects and prognosis. In several trials, exploratory analyses showed no positive prognostic effect of 1st-line antiEGFR antibody in mBRAF mCRC. However, in clinical setting, we often encounter effective cases of antiEGFR antibody in mBRAF mCRC.

Methods

50 patients(pts) with RAS wild mCRC treated with 1st-line mFOLFOX6+anti- EGFR antibody between 5/2012 and 3/2017 were retrospectively analyzed. Median age: 64(41-83). Gender: male 31, female19. Performance status (PS):0-1 48pts, >2 2 pts. Sidedness: Rt-s tumor 12 pts, Lt-s tumor 38(including 17 rectal pts). 7 pts had mBRAF (14%, 5 sRt pts, 2 sLt pts).

Results

The median follow-up time was 28 months(m) (IQR, 14-52). Overall mOS was 29.2m (95%CI; 20.4-32.6), and mPFS was 12.0m (95%CI; 8.0-17.0). Partial responses (PR by RECIST1.1) and early tumor shrinkages (ETS) were observed in 70.5% pts. In the analysis of sidedness and BRAF: mOS; sRt 24.5m, sLt 29.2m (HR 0.683, p = 0.503), sRt mBRAF 20m. ETS; sRt 41.7%, sLt 81.3%, sRt mBRAF 20% (1/5 case). In this sRt mBRAF patient with positive ETS, hepatic metastases were excised after achieving PR by 1st-line mFOLFOX6+antiEGFR antibody, and he has survived 4 years after surgery without any sign of recurrence.

Conclusions

In sRt mBRAF mCRC, some patients show good responses to antiEGFR antibody, and a clinical biomarker is needed to distinguish such pts responsive to the 1st-line antiEGFR antibody. ETS, even though on treatment marker, might be one of the candidates of judging the efficacy.

Editorial acknowledgement

Clinical trial identification

UMIN000031535.

Legal entity responsible for the study

Kyoto Katsura Hospital.

Funding

Has not received any funding.

Disclosure

The author has declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.